EHA signs a tripartite agreement with Roche Diagnostics and Roche Pharma

The General Healthcare Authority (EHA) of Egypt has forged a tripartite agreement with Roche Diagnostics and Roche Pharma to revolutionize healthcare through digital transformation. Announced at the fifth Annual Forum on November 26, 2024 - the partnership marks a milestone in advancing digital pathology and data governance in Egypt's healthcare sector.

Aimed at aligning with Egypt's Vision 2030, the agreement underscores the importance of public-private collaboration in delivering comprehensive, high-quality healthcare for all citizens.

How does it work?

The partnership leverages cutting-edge technology and expertise from Roche Diagnostics and Roche Pharma to modernize healthcare operations in Egypt. Through this agreement, Roche Diagnostics will supply advanced laboratory equipment — including the "Ventana DP 600" slide scanner — which facilitates high-precision digital pathology by scanning up to 240 slides simultaneously. This innovation replaces traditional microscope-based analysis to enable faster and more accurate diagnoses.

In addition, Roche is committed to knowledge sharing, offering training programs for medical professionals and facilitating field visits to international healthcare facilities. Strategic consultations and collaborations with accreditation and quality assurance companies will further optimize laboratory operations and enhance healthcare resource allocation.

The agreement also focuses on implementing a fully digital pathology system at the Ismailia Medical Complex. This shift ensures improved diagnostic accuracy, streamlined workflows, and remote analysis capabilities — reducing time and effort while improving patient outcomes.

Why does it matter?

This partnership is an important step towards transforming healthcare in Egypt. The integration of digital pathology and data governance enhances the quality and efficiency of medical services, ensuring timely and accurate diagnoses that support better treatment decisions.

As Dr. Ahmed El-Sobky, Chairman of the General Healthcare Authority, remarked, "This collaboration accelerates the adoption of modern technology in the healthcare sector, positively reflecting on the services provided to citizens."

Moreover, the partnership supports Egypt's Vision 2030 by improving healthcare accessibility and quality. Through initiatives such as the Telemedicine program, introduced in 2022, the collaboration expands healthcare services beyond Cairo — bridging gaps in underserved regions.

Dr. Liliane Kanaan, General Manager of Roche Diagnostics in Egypt and North Africa, highlighted the significance of this alliance: "We are proud of this strategic collaboration in digital pathology solutions, which will contribute to improving the patient journey across all stages of diagnosis and treatment."

The context

The partnership comes at a time when Egypt is prioritizing healthcare reform and digital transformation. Over recent years, the country has made notable strides in advancing healthcare infrastructure and implementing universal health insurance. This collaboration aligns seamlessly with these efforts, leveraging global expertise to address local challenges.

The digital transformation initiative is a continuation of Egypt's journey toward comprehensive, sustainable healthcare services. By introducing advanced technologies such as the "Ventana DP 600" and facilitating data governance, the agreement sets a benchmark for future public-private partnerships.

The tripartite agreement between EHA, Roche Diagnostics, and Roche Pharma exemplifies the power of collaboration in driving systemic change. By combining technological innovation with strategic healthcare planning, the partnership ensures that Egypt remains at the forefront of regional healthcare excellence — meeting the needs of its citizens while setting a standard for the global community.